Analyst firms · BofA Securities · NVAX
BofA Securities NVAX price target and rating history
Novavax Inc. (NVAX) · Health Care
BofA Securities rates Novavax Inc. (NVAX) Underperform with a $7 price target, as of its latest action on Aug 20, 2025. It has published 3 rating actions on NVAX since May 2022, including 1 upgrade and 1 downgrade.
- Current rating
- Underperform
- Price target
- $7
- Median target, all firms
- Too few
- Actions on NVAX
- 3
BofA Securities price target on NVAX
Every BofA Securities rating on NVAX
- Aug 20, 2025
- May 10, 2024
- May 20, 2022
Questions about BofA Securities and NVAX
- What is BofA Securities's price target for NVAX?
- BofA Securities's latest stated price target for Novavax Inc. (NVAX) is $7, from its action on Aug 20, 2025.
- What is BofA Securities's rating on NVAX?
- BofA Securities rates NVAX Underperform, a bearish rating, as of Aug 20, 2025.
- When did BofA Securities last change its view on NVAX?
- On Aug 20, 2025, BofA Securities downgrades to Underperform from Neutral, price target $7.
More NVAX rating histories
All BofA Securities ratingsNVAX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.